AGIOAGIOS PHARMACEUTICALS, INC.
Pharmaceutical Preparations · $1.8B market cap · 200,000 employees
0.6×
Less likely than average to be taken private
Top 32% of the Russell 3000 for a buyout by a private-equity firm, holdco or insiders. How it works
Takeover signals
What an activist or buyer would see: cheap, overpaid, diluted or under pressure.
6of 15 firedHow well they predict deals →
- TSR below peersYes5 of 5 years3+ of last 5 years
- Dilutive SBCYes97% of revenueOver 10% of revenue
- Shareholder dissentYes68% lowest supportAny vote under 80% support
- Low revenue per employeeYes$270 · 7th pctBottom quartile of its SIC industry
- Quiet on AIYes0.3 per 10K words · 16th pctBottom quartile of AI mentions in 10-Ks
- Buyout-sizedYes$1.8B market capMarket cap $500M–$5B
9 other checks
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Net cashNo—More cash than debt, positive EBITDA
- Recurring revenueNo3 of 1010-K business scored 7+ of 10 for recurring revenue
- AI-rollup shapedNo0 of 1010-K business scored 5+ of 10 as an AI-rollup target
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$5M netNet sales over $10M in 12 months
Deal filings
| Filed | Form | Acquirer | Price | Premium |
|---|---|---|---|---|
| Feb 11, 2021 | DEFM14A | Servier Pharmaceuticals, LLC | $1800000000.00 | 30% |
Key numbers
- Revenue
- $54M
- 48% YoY
- Operating margin
- -873.9%
- 25% YoY
- EBITDA
- −$467M
- 11% YoY
- Net debt / EBITDA
- —
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $14M | $27M | $36M | $54M | 48% |
| Operating income | −$378M | −$389M | −$391M | −$426M | −$472M | 11% |
| Net income | $1.6B | −$232M | −$352M | $674M | −$413M | 161% |
| Operating cash flow | −$407M | −$309M | −$296M | −$390M | −$373M | 4.3% |
| Capex | $6M | $5M | $999K | $2M | $4M | 156% |
| Stock-based comp | $54M | $49M | $45M | $43M | $53M | 23% |
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Apr 5, 2021 | BRISTOL MYERS SQUIBB CO | SC 13D/A | 0.0% | Passive |
| Nov 14, 2019 | Celgene European Investment Co LLC | SC 13D/A | 10.6% | Passive |
Insider trading
−$5Mnet selling by insiders, open market, last 12 months
Bought $0 · 0 tradesSold $5M · 42 trades
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 63 | 120 |
| FY2024 | — | — | 76 | 91 |
| FY2023 | — | — | 51 | 92 |
| FY2022 | — | — | 65 | 89 |
| FY2021 | — | — | 76 | 99 |